Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Nokia Corp (NOK) Price & Performance

Charles River Laboratories Intl. IncTrade
Nokia CorpTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Nokia Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $226.02 (market cap $11.14B), while Nokia Corp trades at $10.89 (market cap $65.32B). The key difference: Nokia Corp is far larger — about 5.9× Charles River Laboratories Intl. Inc's market cap, and Nokia Corp pays a 1.4% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

CRLNOK
Market Cap
$11.14B$65.32B
Sector
HealthTechnology
52-Week High
$233.60$16.83
52-Week Low
$145.57$4.05
Enterprise Value
$14.00B$62.14B
Dividend Yield
1.4%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

Nokia Corp

Nokia (NOK) trades at $11.675, down 6.04% today amid a broader technical pullback despite strong AI-driven momentum. The stock has surged over 100% YTD on AI infrastructure partnerships, including a $1 billion deal with Nvidia. Recent earnings show mixed results with Q1 2026 missing expectations, but Q3 and Q4 2025 beat estimates. Valuation metrics appear elevated with a P/E of 73.32, while profitability remains modest with a 3.98% net margin. Cash flow trends show volatility, with 2025 net cash flow negative at -$1.16 billion.

Nokia's AI transformation presents significant upside potential with analyst consensus target of $18.00 (54% upside), but high valuation and execution risks warrant caution. The company's pivot to AI networking infrastructure is gaining traction, though supply constraints and heavy R&D spending could pressure near-term profitability. Technical indicators suggest near-term bearish pressure with key support at $11.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Nokia Corp

Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.

Read more on NOK